Pfizer Will Study Oxecta Abuse/Misuse Potential Post-Market
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA okays the opioid, which contains abuse-resistant components, with labeling about a study that found the drug less likeable than immediate-release oxycodone.
You may also be interested in...
Keeping Track: Cardio, Antibiotic Approvals Put FDA Over Last Year's Novel Drug Count
The latest drug development news and US FDA highlights from our Performance Tracker.
When Is An Abuse-Deterrent Claim FDA Approved?
Agency says it is seeing confusion in the marketplace when it comes to distinguishing between agency-approved labeling claims and advertising about products that are intended to be abuse deterrent.
Purdue NDA For Oxycodone/Naloxone Combo Tests New FDA Policy
The sponsor believes its data package could support a labeling claim that the drug “is expected to result in a meaningful reduction in abuse”; the agency’s review could indicate the strength of data needed to support such a claim.